European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish adaptation;Guía europea de prevención cardiovascular en la práctica clínica. adaptación española del CEIPC 2008

Revista Espanola de Salud Publica

Volumn 82, Issue 6, 2008, Pages 581-616

  Lobos, José Ma ^a,e   Royo Bordonada, Miguel A ^b   Brotons, Carlos ^c   Álvarez Sala, Luís ^d   Armario, Pedro ^e   Maiques, Antonio ^c   Mauricio, Dídac ^f   Sans, Susana ^g   Villar, Fernando ^d   Lizcano, Angel ^h   Gil Núñez, Antonio ⁱ   Álvaro, Fernando De ^j   Conthe, Pedro ^k   Luengo, Emilio ^l,m   Río, Alfonso Del ^m   Cortés Rico, Olga ⁿ   Santiago, Ana De ^e   Vargas, Miguel A ^e   Martínez, Mercedes ^e   Lizarbe, Vicenta ^o  

^a CEIPC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Programa de Actividades Preventivas y Promocion de la Salud PAPPS   (Spain)

^d Sociedad Española de Arteriosclerosis   (Spain)

^e Sociedad Española de Hipertensión Liga Española de la Lucha Contra la HTA ^*  (Spain)

^f Sociedad Espanola de Diabetes   (Spain)

^g Sociedad Española de Salud Pública y Administración Sanitaria

^h Federación Española de Enfermería de Atención Primaria

ⁱ Sociedad Española de Neonatología   (Spain)

^j GEENDIAB Grupo Español para el estudio de la Nefropatía Diabética   (Spain)

^k Sóciedad Espanóla de Medicina Interna   (Spain)

^l Nacional de Prevención Sociedad Europea de Cardiología European Society of Cardiology

^m Sociedad Espanola de Cardiologia   (Spain)

ⁿ Hospital Clínico   (Spain)

^o MINISTERIO DE SANIDAD Y CONSUMO   (Spain)

more..

Author keywords

Cardiovascular diseases; Cardiovascular prevention; Cardiovascular risk

Indexed keywords

CHOLESTEROL;

ADULT; AGE; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DIET; EUROPE; EXERCISE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; RISK FACTOR; SMOKING; SPAIN;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIET; EUROPE; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SMOKING; SPAIN;

EID: 60849113701     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: 10.1590/S1135-57272008000600002     Document Type: Article

References (89)

1. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: fourth joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007; 28: 2375-2414.
2. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al.. Guías de práctica clínica sobre prevención de la enfermedad cardiovascular: versión resumida. Rev Esp Cardiol. 2008;61:82.e1-49.
3. Lobos JM, Brotons C. Nuevas estrategias en prevención cardiovascular. Aten Primaria 2004; 34 (8): 389-91.
4. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conthe P et al. Adaptación española de la guía europea de prevención cardiovascular Rev Esp Salud Pública 2004; 78: 435-438.
5. Brotons C, Royo-Bordonada MA, Álvarez-Sala L, Armario P, Artigao R, Conthe P et al. Adaptación española de la guía europea de prevención cardiovascular. Neurología. 2004; 19:438-9.
6. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Ministerio de Sanidad y Consumo, 2004.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardio Prev Rev 2003; 10 (Supl.1): S1-S78, 2003.
8. Sans S, Fitzgerald AP, Royo D, Conroy R, Grahan I.. Calibración de la tabla SCORE de riesgo cardiovascular para España. Rev Esp Cardiol. 2007;60:476-85
9. Instituto Nacional de Estadística. Defunciones según la Causa de Muerte 2006 Tablas Nacionales. Defunciones por causas (lista reducida), sexo y edad. (Consultado en 2008, Disponible en http://www.ine.es/inebase/cgi/ axi )
10. F. Villar, JR Banegas, J de Mata Donado, F Rodríguez Artalejo. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2007. Sociedad Española de Arteriosclerosis.
11. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000. N Engl J Med 2007;356 (23):2388-2398.
12. Plan Integral de Cardiopatía Isquémica 2004-2007. Secretaría General de Sanidad - Agencia de Calidad del Sistema Nacional de Salud.. Madrid: Ministerio de Sanidad y Consumo; 2003.
13. Estrategia NAOS: Estrategia para la nutrición, actividad física y prevención de la obesidad. Agencia Española de Seguridad Alimentaria. Ministerio de Sanidad y Consumo, 2005.
14. Rose G. The strategy of prevention: lessons from cardiovascular disease. BMJ. 1981;282: 1847-51.
15. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and the European Society of Hypertension. Atherosclerosis 1994; 110:121-61.
16. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on coronary prevention. Eur Heart J. 1998; 19: 1434-503.
17. Conroy R, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24:987-1003.
18. The health consequences of smoking: a report of the Surgeon General. Washington: US Department of Health and Human Services; 2004. Disponible en: www.surgeongeneral.gov/library/smokingconsequences/
19. The Health Benefits of Smoking Cessation. Washington: US Department of Health and Human Services; 1990.
20. McEwen A, Hajek P, McRobbic H, West R. Manual of Smoking Cessation. Oxford: Blackwell; 2006.
21. Wajchenberg B. Subcutanuous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000; 21:697-738.
22. Despres J, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoprotein, and cardiovascular disease. Arteriosclerosis. 1990;10:497-511.
23. World Health Organization Consultation of Obesity. Obesity: Preventing and Managing the Global Epidemic. Geneva: Division of Non-communicable Diseases, Programme of Nutrition, Family and Reproductive Health, WHO; 1998.
24. National Heart, Lung, and Blood Institute Obesity Education Initative Expert Panel. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Obes Res. 1998; 6: S51-209.
25. Franco O, De Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med. 2005;165: 2355-60.
26. Taylor R, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004; 116:682-92.
27. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-74.
28. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996; 347:1141-5.
29. Vasan R, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001; 358:1682-6.
30. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187
31. PROGRESS Collaborative Group. Randomised trial of a perindopril- based blood-pressure-lowe- ring regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-41.
32. HOPE: Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and micro-HOPE substudy. Lancet. 2000; 355:253-9.
33. Casas J, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AR, et al. Effects of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005; 366:2026-33.
34. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003.
35. Mancia G, Grassi G, Zancheti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006; 24:3-10.
36. Waeber B, Burnier M, Brunner HR. Compliance with antihypertensive therapy. Clin Exp Hypertens. 1999;21: 973-85.
37. Clement D, De Buyzere ML, De Bacquer DA, De Leeuw PW, Duprez DA, Fagard RH, et al; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348: 2407-15.
38. Alvarez-Sala LA, Suarez C, Mantilla T, et al. Estudio PREVENCAT: control del riesgo cardiovascular en atención primaria. Med Clin (Barc) 2005; 124(11): 406-10.
39. Banegas JR, Guallar-Castillon P, Rodriguez-Artalejo F, Graciani A, Lopez-Garcia E, Ruilope LM. Association between awareness, treatment, and control of hypertension, and quality of life among older adults in Spain. Am J Hypertens 2006; 19 (7):686-93.
40. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267-78.
41. Colhoun H, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo controlled trial. Lancet 2004;364:685-96.
42. Ray K, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al; PROVE IT-TIMI 22 Investigators. Early and late benefit of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE-IT-TIMI22 trial. J Am Coll Cardiol. 2005; 46:1405-10.
43. Nissen S, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295:1556-65.
44. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, De Boer MJ, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28: 88-136.
45. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358:2560.
46. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358:2545-59.
47. Alberti K, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005; 366:1059-62.
48. Rees K, Bennett P,West R, Davey SG, Ebrahim S. Psychological Interventions for Coronary Heart Disease (Cochrane Review). Oxford: Update Software; 2004.
49. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105:1135-43.
50. Ridker P, Hennekens CH, Buring JE, Rifai N. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-43.
51. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004; 351:2611-8.
52. Lowe G. Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol. 2006;133: 232-50.
53. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387-97.
54. Geelen A, Brouwer IA, Schouten EG, Maan AC, Katan MB, Zock PL. Effects of n-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. Am J Clin Nutr. 2005;81: 416-20.
55. Myers R, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990; 120:963-9.
56. Patterson D, Slack J. Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet. 1972; 1:393-9.
57. Holla O, Teie C, Berge KE, Leren TP. Identification of deletions and duplications in the low density lipoprotein receptor gene by MLPA. Clin Chim Acta. 2005; 356:164-71.
58. Heath K, Gahan M, Whittall RA, Humphries SE. Low-density lipoprotein receptor gene (LDLR) world-wide website in familial hypercholesterolaemia: update, new features and mutation analysis. Atherosclerosis. 2001;154: 243-6.
59. Heath K, Humphries SE, Middleton-Price H, Boxer M. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet. 2001;9:244-52.
60. Fouchier S, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet. 2001;109:602-15.
61. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10- year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002; 105:310-5.
62. Von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. Atherosclerosis. 2006; 186:231-9.
63. Kachelriess M, Kalender WA. Electrocardiogramcorrelated image reconstruction from subsecond spiral computed tomography scans of the heart. Med Phys. 1998;25:2417-31.
64. Tedeschi-Reiner E, Strozzi M, Skoric B, Reiner Z. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. Am J Cardiol. 2005;96:1107-9.
65. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, et al. Cardiovascular disease in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J. 2006;27:994-1005.
66. Berl T, Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006; 1:8-18.
67. Fox C, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291: 844-50.
68. Sarafidis P, Whaley-Connell, Sowers J, Bakris GL. Cardiometabolic syndrome and chronic kidney disease: what is the link? JCMS. 2006; 1:58-65.
69. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, et al. The association among renal insufficiency, pharmacotherapy and outcomes in 6247 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-92.
70. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk people. BMJ. 2002; 324:71-86.
71. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med. 2001; 345: 494-502.
72. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89.
73. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al, for the CHARISMA Investigators. Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1-12.
74. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364 (9431):331-7
75. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001; 85:265-7113.
76. Freemantle N, Cleland J,Young P, Mason J, Harrison J. Beta-blokade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
77. Brophy JM, Joseph L, Rouleau JL. Beta-blokers in congestive Heart Failure. A Bayesian metaanalysis Ann Intern Med 2001; 134: 550-560.
78. Flather MD, Yusuf Y, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedrsen C, Ball S, Pogue J, Moyé L, Braunwald E, for the ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81.
79. ACE Inhibitor Myocardial Infartion Collaborative Group. Indication for ACE Inhibitors in the early treatment of acute myocardial infartion: systematic overview of individual data from 100.000 patients in randomized trials. Circulation 1998; 97: 2202-12.
80. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005 ; 36:1218-22.
81. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High Risk Acute Myocardial Infarction Ann Intern Med. 2004;141: 693-704.
82. The ONTARGET Investigators. Telmisartan, ramipril or both in patient ar high risk for vascu ar events. N Engl J Med 2008; 358: 1547-59
83. Diez Tejedor E, Fuentes B, Gil Núñez AC, Gil Peralta A, Matías Guiu J, por el comité ad hoc del Grupo de Estudio de Enfermedades Cerebrovasculares de la SEN. Guía para el tratamiento preventivo de la isquemia cerebral En Diez Tejedor E (ed.). Guía para el diagnostico y tratamiento del ictus. Prous Science,Barcelona, 2006:133-183.
84. EUROASPIRE Study Group: European Action on Secondary Prevention by Intervention to Reduce Events. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J. 1997; 18: 1569-82.
85. EUROASPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention programmes: a comparison of EUROASPIRE I & II in 9 countries. EUROASPIRE I & II Group. European Action on Secondary prevention by Intervention to Reduce Events. Lancet. 2001; 357: 995-1001.
86. Orozco-Beltrán D, Brotons C, Moral I, Soriano N, Del Valle MA, Rodríguez AI et al (en representación de los investigadores del estudio PREse-AP). Determinantes del control de la presión arterial y los lípidos en pacientes con enfermedad cardiovascular (estudio PREseAP). Rev Esp Cardiol 2008; 61: 317 - 321
87. Gil-Núñez A, Vivancos J, Gabriel R en nombre del Proyecto Ictus del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología. Diagnóstico y prevención secundaria del infarto cerebral en España. Estudio DIAPRESIC. Med Clín 2008 (en prensa)
88. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J , Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O, on behalf of EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371: 1999-2012
89. Primera Conferencia de Prevención y Promoción de la Salud en la Práctica Clínica en España. Madrid: Ministerio de Sanidad y Consumo, 2007. Disponible en: www.msc.es/profesionales/salud-Publica/ prevPromocion/conferenciaPPS/conferencia.htm.